Skip to content

Study · Observational study · n = 48 · 1996

2 results

Growth hormone (GH)-releasing hormone-induced GH response in hypothalamic amenorrhea: evidence of altered central neuromodulation.

Genazzani AD, Petraglia F, Gastaldi M, Gamba O, Corazza F, D'Ambrogio G, Genazzani AR

Fertility and sterility1 May 1996Cited by 6 (Europe PMC)

PMID8612852 (opens in a new tab)DOI10.1016/s0015-0282(16)58264-8 (opens in a new tab)PepBankPUB-08612852
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with weight-loss-related hypothalamic amenorrhea, maximal GH release after GH-RH was higher than in healthy controls.

    In plain wordsAfter a GH-RH test, patients with weight-loss-related absent periods released more growth hormone at the peak than healthy controls.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH-RH-induced maximal GH release
    Study

    n = 48

    Comparator
    Healthy controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg body weight · intravenousAs given in this study (human).

    Source sentences

    Summary
    The GH-RH--induced GH response evaluated as maximal release and as area under the curve (AUC) was higher in amenorrheic patients than in control subjects.
    2 context sentences
    Summary · context
    Patients affected by weight-loss-related hypothalamic amenorrhea (n = 28) were studied and compared with 20 healthy controls.
    Summary · context
    All subjects underwent a GH-RH test (GEREF, Sereno, Rome, Italy) (1 microgram/kg body weight IV).
  2. 02HumanObservational studyEfficacy outcome

    In patients with weight-loss-related hypothalamic amenorrhea, the GH area under the curve after GH-RH was higher than in healthy controls.

    In plain wordsAfter a GH-RH test, patients with weight-loss-related absent periods released more total growth hormone than healthy controls.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH-RH-induced GH area under the curve
    Study

    n = 48

    Comparator
    Healthy controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg body weight · intravenousAs given in this study (human).

    Source sentences

    Summary
    The GH-RH--induced GH response evaluated as maximal release and as area under the curve (AUC) was higher in amenorrheic patients than in control subjects.
    2 context sentences
    Summary · context
    Patients affected by weight-loss-related hypothalamic amenorrhea (n = 28) were studied and compared with 20 healthy controls.
    Summary · context
    All subjects underwent a GH-RH test (GEREF, Sereno, Rome, Italy) (1 microgram/kg body weight IV).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.